JAC Advance Access originally published online on September 22, 2006
Journal of Antimicrobial Chemotherapy 2006 58(5):916-929; doi:10.1093/jac/dkl354
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review |
Two decades of imipenem therapy
1 Institut for Medical Microbiology and Epidemiology of Infectious Diseases, University of Leipzig D-04103 Leipzig, Germany 2 R M Alden Research Laboratory Santa Monica, CA 90404, USA 3 Institut Clínic de Pneumologia i Cirurgia Toràcica, Hospital Clínic de Barcelona Spain
*Corresponding author. Tel: +49-341-97-15-200; Fax +49-341-97-15-209; E-mail: acr{at}medizin.uni-leipzig.de
Imipenem, the first carbapenem discovered, was developed more than two decades ago in response to an unmet need for a highly potent, broad-spectrum antimicrobial agent with a strong safety profile. It has since been used to treat more than 26 million patients. In an era where antibiotic use has driven antibiotic resistance, choosing appropriate initial therapy for serious infection is critical. Appropriate antibiotic regimens must cover all likely pathogens, be administered promptly at the correct dosage and dosing interval, be well tolerated and prevent the emergence of resistance. While imipenem was initially reserved for use in intractable, serious infections, the benefits of early aggressive therapy are now known, making imipenem a core agent in de-escalation therapy due to proven efficacy and safety for indications such as nosocomial pneumonia, intra-abdominal infection, sepsis and febrile neutropenia. De-escalation therapy with an agent such as imipenem minimizes resistance development by initiating aggressive initial treatment and then tailoring therapy based on patient response and culture results, switching to a less expensive, narrower spectrum antibiotic regimen or shortening the duration of therapy. Imipenem has maintained sustained clinical efficacy, tolerability and in vitro activity against important bacterial pathogens for two decades. We review the factors that continue to make imipenem as appropriate an agent for de-escalation therapy now as it was 20 years ago.
Keywords: antibiotics , appropriate therapy , carbapenems , de-escalation , infections , pneumonia
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Cirillo, N. Vaccaro, K. Turner, B. Solanki, J. Natarajan, and R. Redman Pharmacokinetics, Safety, and Tolerability of Doripenem After 0.5-, 1-, and 4-Hour Infusions in Healthy Volunteers J. Clin. Pharmacol., July 1, 2009; 49(7): 798 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Souli, P. D. Rekatsina, Z. Chryssouli, I. Galani, H. Giamarellou, and K. Kanellakopoulou Does the Activity of the Combination of Imipenem and Colistin In Vitro Exceed the Problem of Resistance in Metallo-{beta}-Lactamase-Producing Klebsiella pneumoniae Isolates? Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2133 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jaruratanasirikul and T. Sudsai Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion J. Antimicrob. Chemother., March 1, 2009; 63(3): 560 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yamada, T. Watanabe, N. Baba, Y. Takeuchi, F. Ohsawa, and S. Gomi Crystal Structures of Biapenem and Tebipenem Complexed with Penicillin-Binding Proteins 2X and 1A from Streptococcus pneumoniae Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2053 - 2060. [Abstract] [Full Text] [PDF]
|
|